経動脈的化学塞栓療法の世界市場

経動脈的化学塞栓療法の世界市場は2030年までに218億米ドルに達する見込み

2024年に168億米ドルと推定される経動脈的化学塞栓療法の世界市場は、2024～2030年の分析期間にCAGR 4.5%で成長し、2030年には218億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである化学療法剤は、CAGR 4.3%を記録し、分析期間終了時には115億米ドルに達すると予測されます。放射線治療薬セグメントの成長率は、分析期間中CAGR 5.1%と推定されます。

米国市場は推定46億米ドル、中国はCAGR8.1％で成長予測

米国の経動脈的化学塞栓療法市場は2024年に46億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに45億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.9%と3.5%と予測されています。欧州では、ドイツがCAGR 2.6%で成長すると予測されています。

世界の「経動脈的化学塞栓療法」市場- 主要動向と促進要因のまとめ

経動脈的化学塞栓療法が世界の肝がん治療のスタンダードになりつつある理由とは？

経動脈的化学塞栓療法（TACE）は、原発性肝がんの中で最も一般的な形態である中期の肝細胞がん（HCC）に対する治療法として好まれ、標準化されつつあります。全身化学療法とは異なり、TACEは高用量の化学療法を腫瘍に栄養を供給する肝動脈に直接投与すると同時に血液供給を遮断することで、薬剤の標的曝露と腫瘍局所の壊死をもたらします。この二重のメカニズムにより、外科的切除や肝移植が不適格な患者に特に有効であることが証明されています。TACEはまた、移植を待つ患者のつなぎ療法としても採用されており、病状の進行を安定させるのに役立っています。世界的には、慢性B型肝炎やC型肝炎の感染、非アルコール性脂肪性肝疾患（NAFLD）、アルコール性肝障害などの要因により、肝がんの発生率が上昇しています。このような動向により、TACEのような局所療法に対する需要が高まっています。TACEは、より低い全身毒性プロファイルで生存率と病勢コントロールの改善をもたらします。国際的な腫瘍学会による新たなガイドラインは、TACEを肝悪性腫瘍の最前線または併用療法として推奨しており、これにより治療経路におけるTACEの中心的役割が強化され、世界中の医療従事者の間で採用が進んでいます。

ドラッグデリバリーの革新と画像技術はTACEの治療成績をどのように向上させているか？

塞栓物質、カテーテル技術、画像誘導システムの進歩により、TACEの有効性は著しく向上しています。薬剤溶出性ビーズ（DEB）は、腫瘍部位での化学療法剤の制御および徐放を可能にし、多くの市場で従来のリピオドールベースの製剤に取って代わり、全身への曝露を減らし奏効率を向上させています。マイクロカテーテルとステアラブルデリバリーシステムの技術的向上により、複雑な血管解剖を正確にナビゲートすることが可能になり、健康な肝臓組織へのダメージを最小限に抑えることができるようになりました。同時に、コーンビームCTや3Dアンギオグラフィーのようなリアルタイム・イメージング・モダリティーは、治療中の可視化に革命をもたらし、高度にターゲットを絞ったデリバリーや治療の成功を即座に確認することを可能にしました。これらの技術革新はまた、腫瘍の大きさ、位置、血管が塞栓の種類、粒子径、投与スケジュールの決定に織り込まれるような、個別化された治療計画への道を開いた。さらに、画像解析におけるAIの統合は、インターベンショナル・ラジオロジストによる治療前計画と治療後のアウトカム評価を支援し、一貫性と長期予後を改善し始めています。こうしたテクノロジー主導の改善は、臨床転帰を向上させるだけでなく、TACEの候補者プールを拡大することにもつながっています。

世界のヘルスケア情勢はTACEの普及に向けた準備が整っているか？

世界のヘルスケアエコシステムは、インターベンショナルラジオロジーインフラの拡大と訓練を受けた専門医の増加に支えられ、経動脈的化学塞栓療法の広範な導入にますます前向きになっています。高所得国では、洗練された画像診断室、集学的腫瘍委員会、腫瘍学専用パスウェイの存在により、TACEを肝がん治療のアルゴリズムにシームレスに組み込むことが可能になっています。一方、中所得国では、先進的な手術や全身療法へのアクセスが制限されている資源制約のある環境におけるTACEの価値を認識し、低侵襲のがん治療に多額の投資を行っています。肝がんの罹患率が特に高いアジア太平洋地域では、各国政府が公的保険制度や国のがん対策プログラムにTACEを組み込んでおり、市場の急速な拡大に拍車をかけています。外来手術センターや腫瘍専門病院への民間セクターの投資も、都市部や都市近郊地域におけるTACEの利用可能性の向上に寄与しています。しかし、低所得国では不十分な画像診断機能と熟練したインターベンショナルラジオロジストの不足が課題として残っています。移動式IRユニット、トレーニングプログラム、官民パートナーシップを通じてアクセスを改善しようとする国際医療機関の取り組みは、こうした格差に対処し始め、この延命治療へのアクセスを徐々に民主化しつつあります。

経動脈的化学塞栓療法市場の成長はいくつかの要因に牽引されている...

経動脈的化学塞栓療法市場の成長は、疾病の流行、医療技術革新、ヘルスケアシステムの進化に根ざしたいくつかの要因によって牽引されています。主な促進要因は、高齢化、ウイルス性肝炎、アルコール摂取、代謝障害に後押しされた肝臓がんの世界の負担増です。患者数が増加するにつれて、治癒的治療と緩和的治療の間の治療ギャップを埋めるTACEのような中間的治療に対するニーズも高まっています。技術的な観点からは、次世代塞栓剤、改良されたカテーテルナビゲーションツール、AIを活用した画像解析の開発により、手技の有効性と安全性が向上しています。ヘルスケアプロバイダーは、全身化学療法や手術と比較して低侵襲で回復までの時間が短く、合併症発生率が低いTACEを受け入れています。さらに、外来でのインターベンショナル腫瘍学的治療に対する嗜好の高まりにより、病院と専門クリニックの両方の環境でTACEの需要が拡大しています。特に先進国や急速に経済が発展している諸国では、保険償還が合理化され、TACEが第一選択治療として適用されるようになり、患者へのアクセスが増加しています。機器メーカー、製薬会社、およびインターベンショナルラジオロジーネットワーク間の戦略的提携も、技術革新と市場浸透を促進しています。これらの要因が相まって、TACEは世界的に肝がんの集学的治療における重要な柱となっています。

セグメント

製品タイプ（化学療法剤、放射線治療剤、薬剤溶出粒子）、適応症（切除不能肝細胞がん、早期肝細胞がん）、エンドユーザー（病院、診療所、がん研究センター、その他のエンドユーザー）

調査対象企業の例（注目の合計42社）

• Advaxis Inc.
• Bayer AG
• Bellicum Pharmaceuticals
• Boston Scientific Corporation
• CELGENE Corporation
• Cook Medical
• F. Hoffmann-La Roche Ltd
• Hikma Pharmaceuticals PLC
• Isofol Medical AB
• Kaneka Corporation
• Medtronic plc
• Merck & Co., Inc.
• Merit Medical Systems, Inc.
• Nippon Kayaku Co., Ltd.
• Novartis AG
• Pfizer Inc.
• Siemens Healthineers AG
• Sirtex Medical Limited
• Spectrum Pharmaceuticals, Inc.
• Terumo Corporation

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Transarterial Chemoembolization Market to Reach US$21.8 Billion by 2030

The global market for Transarterial Chemoembolization estimated at US$16.8 Billion in the year 2024, is expected to reach US$21.8 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Chemotherapeutic Agents, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$11.5 Billion by the end of the analysis period. Growth in the Radio Therapeutic Agents segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.6 Billion While China is Forecast to Grow at 8.1% CAGR

The Transarterial Chemoembolization market in the U.S. is estimated at US$4.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.5 Billion by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 3.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Global "Transarterial Chemoembolization" Market - Key Trends & Drivers Summarized

Why Is Transarterial Chemoembolization Becoming a Standard for Liver Cancer Treatment Worldwide?

Transarterial chemoembolization (TACE) has emerged as a preferred and increasingly standardized therapy for intermediate-stage hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Unlike systemic chemotherapy, TACE delivers high-dose chemotherapy directly into the hepatic artery feeding the tumor while simultaneously blocking the blood supply, leading to targeted drug exposure and localized tumor necrosis. This dual mechanism has proven particularly effective in patients ineligible for surgical resection or liver transplantation. TACE is also being adopted as a bridging therapy for patients awaiting transplantation, helping to stabilize disease progression. Globally, the incidence of liver cancer is rising due to factors such as chronic hepatitis B and C infections, non-alcoholic fatty liver disease (NAFLD), and alcohol-related liver damage. These trends have increased demand for locoregional therapies like TACE, which offer improved survival rates and disease control with a lower systemic toxicity profile. Emerging guidelines by international oncology societies are endorsing TACE as a frontline or combination treatment for liver malignancies, thereby reinforcing its central role in therapeutic pathways and boosting adoption among healthcare providers worldwide.

How Are Drug Delivery Innovations and Imaging Technologies Enhancing TACE Outcomes?

The effectiveness of TACE has significantly improved through advancements in embolic materials, catheter technology, and imaging guidance systems. Drug-eluting beads (DEBs), which allow for controlled and sustained release of chemotherapy agents at the tumor site, have largely replaced traditional lipiodol-based formulations in many markets, reducing systemic exposure and improving response rates. Technological enhancements in microcatheters and steerable delivery systems have made it possible to navigate complex vascular anatomies with precision, minimizing damage to healthy liver tissue. At the same time, real-time imaging modalities such as cone-beam CT and 3D angiography have revolutionized intra-procedural visualization, allowing for highly targeted delivery and immediate verification of treatment success. These innovations have also paved the way for personalized treatment plans, where tumor size, location, and vascularity are factored into decisions on embolic type, particle size, and dosing schedules. Additionally, the integration of AI in imaging analytics is beginning to assist interventional radiologists in pre-procedural planning and post-procedural outcome assessments, improving consistency and long-term prognoses. These technology-led improvements are not only boosting clinical outcomes but also expanding the candidate pool for TACE.

Is the Global Healthcare Landscape Ready for the Widespread Adoption of TACE?

The global healthcare ecosystem is increasingly receptive to the widespread adoption of transarterial chemoembolization, supported by expanding interventional radiology infrastructure and a growing base of trained specialists. In high-income countries, the presence of sophisticated imaging suites, multidisciplinary tumor boards, and dedicated oncology pathways has allowed for the seamless integration of TACE into liver cancer care algorithms. Meanwhile, middle-income countries are investing heavily in minimally invasive cancer care, recognizing TACE’s value in resource-constrained settings where access to advanced surgery or systemic therapies is limited. In Asia-Pacific, where liver cancer incidence is particularly high, governments are including TACE in public insurance schemes and national cancer control programs, fueling rapid market expansion. Private sector investments in ambulatory surgical centers and oncology-focused hospitals are also contributing to the increased availability of TACE in urban and peri-urban regions. However, challenges remain in low-income countries due to inadequate imaging capabilities and a shortage of skilled interventional radiologists. Efforts by global health organizations to improve access through mobile IR units, training programs, and public-private partnerships are beginning to address these disparities, gradually democratizing access to this life-extending procedure.

The Growth in the Transarterial Chemoembolization Market Is Driven by Several Factors…

The growth in the transarterial chemoembolization market is driven by several factors rooted in disease prevalence, medical innovation, and healthcare system evolution. A primary driver is the rising global burden of liver cancer, fueled by aging populations, viral hepatitis, alcohol consumption, and metabolic disorders. As patient volumes increase, so does the need for intermediate therapies like TACE that fill the treatment gap between curative and palliative care. From a technological perspective, the development of next-generation embolic agents, improved catheter navigation tools, and AI-powered imaging analytics is enhancing procedural efficacy and safety. Healthcare providers are embracing TACE for its minimally invasive profile, shorter recovery times, and lower complication rates compared to systemic chemotherapy or surgery. Additionally, the growing preference for outpatient interventional oncology treatments is expanding demand for TACE in both hospital and specialty clinic settings. Insurance reimbursements, particularly in developed and rapidly developing economies, are being streamlined to cover TACE as a first-line therapy, increasing patient access. Strategic collaborations between device manufacturers, pharma companies, and interventional radiology networks are also fostering innovation and market penetration. Collectively, these factors are positioning TACE as a vital pillar in the multidisciplinary management of liver cancer worldwide.

SCOPE OF STUDY:

The report analyzes the Transarterial Chemoembolization market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Chemotherapeutic Agents, Radio Therapeutic Agents, Drug-Eluting Particles); Indication (Unresectable HCC, Early-Stage HCC); End-Use (Hospitals, Clinics, Cancer Research Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Advaxis Inc.
• Bayer AG
• Bellicum Pharmaceuticals
• Boston Scientific Corporation
• CELGENE Corporation
• Cook Medical
• F. Hoffmann-La Roche Ltd
• Hikma Pharmaceuticals PLC
• Isofol Medical AB
• Kaneka Corporation
• Medtronic plc
• Merck & Co., Inc.
• Merit Medical Systems, Inc.
• Nippon Kayaku Co., Ltd.
• Novartis AG
• Pfizer Inc.
• Siemens Healthineers AG
• Sirtex Medical Limited
• Spectrum Pharmaceuticals, Inc.
• Terumo Corporation

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Transarterial Chemoembolization - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Liver Cancer and Hepatocellular Carcinoma Propels Demand for TACE Procedures
  • Increasing Preference for Minimally Invasive Oncology Treatments Expands TACE Adoption
  • Advancements in Drug-Eluting Beads Technology Strengthen Clinical Outcomes and Market Appeal
  • Expanding Use of TACE in Palliative Cancer Care Throws the Spotlight on Targeted Therapies
  • Growing Acceptance of TACE as a First-Line Treatment Drives Procedural Volumes Globally
  • Integration of Imaging Guidance Systems Enhances Precision and Spurs Market Innovation
  • Favorable Reimbursement Scenarios in Developed Markets Support Wider Procedural Uptake
  • Aging Population and Comorbidities Increase Patient Pool for Non-Surgical Therapies
  • Expansion of Interventional Radiology Infrastructure in Emerging Markets Sustains Global Growth
  • Improved Catheterization Techniques Propel Success Rates and Professional Confidence in TACE
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Transarterial Chemoembolization Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Transarterial Chemoembolization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Transarterial Chemoembolization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapeutic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Chemotherapeutic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Chemotherapeutic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Radio Therapeutic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Radio Therapeutic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Radio Therapeutic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Drug-Eluting Particles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Drug-Eluting Particles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Drug-Eluting Particles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Unresectable HCC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Unresectable HCC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Unresectable HCC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Early-Stage HCC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Early-Stage HCC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Early-Stage HCC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Cancer Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Cancer Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Cancer Research Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 59: China Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Transarterial Chemoembolization by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Transarterial Chemoembolization by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• FRANCE
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 80: France Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 107: UK Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Transarterial Chemoembolization by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• INDIA
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 164: India Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Transarterial Chemoembolization by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Transarterial Chemoembolization by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Transarterial Chemoembolization by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Transarterial Chemoembolization by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
• AFRICA
  • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION